The term "Personalized medicine" is used quite loosely; it basically refers to the use of genetics or other biomarker data to guide patient treatment decisions. These decisions I involve determining which patients should receive particular medicines or quantities of a given drug, or which patients should be given closer monitoring because they are more likely to experience a certain safety risk. The study of genetic variants and their impact on how individuals respond to pharmaceuticals has been referred to as genetics, pharmacogenetics, personalised medicine, and pharmacogenomics. Let's look at how we now treat patients to better appreciate the potential of pharmacogenomics. In the event that you visit the practitioner for high blood pressure, for instance, he or she may likely prescribe you any of a variety of blood pressure drugs based on very little knowledge of what will be effective for you. In fact, you might not even have a good reason for receiving that particular prescription other than the fact because your coverage supports it or because the doctor has some samples on hand. If the prescription doesn't start working after 4 to 6 weeks, it can be changed, or another medication might be given on base of the first.
Submit your abstract Today
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India
Title : Bridging tradition and innovation: Inorganic meets green synthesis
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy